



Dementia & Neuropsychologia

ISSN: 1980-5764

demneuropsych@uol.com.br

Associação Neurologia Cognitiva e do
Comportamento
Brasil

Tenenholz Grinberg, Lea; de Lucena Ferretti, Renata Eloah; Leite, Renata E.P.; Farfel, Jose Marcelo; Pacheco, Silmara P.; Di Lorenzo Alho, Ana Teresa; Grisoli, Renata P.; Matos, Heidy T.M.; Moreira, Eliza G.; Balbino, Erika S.; Oliveira, Katia C.; Rosemberg, Sergio; Barbosa Carvalho, Heráclito; Pasquallucci, Carlos Augusto G.; Saldiva, Paulo Hilario N.; Jacob-Filho, Wilson; Nitrini, Ricardo
Clinicopathological correlates of Alzheimer's disease in a general autopsy series from Brazil
Dementia & Neuropsychologia, vol. 1, núm. 4, octubre-diciembre, 2007, pp. 356-360
Associação Neurologia Cognitiva e do Comportamento
São Paulo, Brasil

Available in: <http://www.redalyc.org/articulo.oa?id=339529000005>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in redalyc.org

redalyc.org

Scientific Information System
Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal
Non-profit academic project, developed under the open access initiative

Clinicopathological correlates of Alzheimer's disease in a general autopsy series from Brazil

Lea Tenenholz Grinberg^{1,2}, Renata Eloah de Lucena Ferretti^{1,3}, Renata E.P. Leite¹, Jose Marcelo Farfel^{1,3}, Silmara P. Pacheco¹, Ana Teresa Di Lorenzo Alho^{1,2}, Renata P. Grisoli^{1,2}, Heidy T.M. Matos^{1,2}, Eliza G. Moreira^{1,2}, Erika S. Balbino^{1,2}, Katia C. Oliveira¹, Sergio Rosemberg¹, Heráclito Barbosa Carvalho⁴, Carlos Augusto G. Pasquallucci¹, Paulo Hilario N. Saldiva¹, Wilson Jacob-Filho³, Ricardo Nitrini⁵

Abstract – The current neuropathological staging models of Alzheimer's disease (AD) have been developed within the last 20 years. Nevertheless, they were mostly tested on Caucasians of Northern European ancestry or on Asians. **Objective:** To verify which of the accepted neuropathologic criteria best discriminates AD from normal aging in a well characterized Brazilian clinicopathological series. **Methods:** A random sample consisting of 89 subjects belonging to the Brazilian Brain Bank of the Aging Brain Study were clinically and neuropathologically fully assessed using immunohistochemistry. Clinical and functional statuses were assessed by interviewing a reliable informant. The Clinical dementia rating scale (CDR) was compared to Braak and Braak stage, the consortium to establish a registry for Alzheimer's disease (CERAD) score and NIA-Reagan (National Institute of Aging - Reagan Institute) score. Subjects with a neuropathologic diagnosis other than AD were excluded (n=27). **Results:** The CDR score distribution for the 62 selected subjects was as follows: CDR0=39, CDR0.5=9, CDR≥1=14. There were no differences regarding age, gender and education among the groups. CDR score correlated best with the CERAD score ($r=0.5303$; $p<0.001$). Braak and Braak stage was significantly higher in subjects with higher CDR. Correlation of the NIA-Reagan criteria was partially disrupted because a large proportion of subjects did not fit any of its categories. **Conclusions:** In this series, CERAD criteria better correlated with the CDR groups. Consistent with earlier studies, some cognitively normal subjects have AD neuropathological diagnosis.

Key words: Alzheimer's disease, dementia, diagnostic criteria, neuropathological criteria, brain bank.

Correlação clinicopatológica na doença de Alzheimer em casuística de autópsia no Brasil

Resumo – Os modelos de estadiamento neuropatológico da doença de Alzheimer (DA) têm sido desenvolvidos nos últimos 20 anos. Entretanto, têm sido quase exclusivamente testados em caucasianos de ascendência nortey-europeia ou em asiáticos. **Objetivos:** verificar quais dos critérios neuropatológicos discrimina melhor entre a DA e o envelhecimento normal em uma casuística clinicopatológica brasileira bem caracterizada. **Métodos:** uma amostra aleatória de 89 casos do Banco Brasileiro de Encéfalos do Estudo de Envelhecimento Cerebral foi submetida à avaliação neuropatológica completa com imunohistoquímica. As condições clínicas e funcionais foram avaliadas mediante entrevista com informante confiável. Os escores na *Clinical Dementia Rating Scale* (CDR) foram comparados com os escores dos estágios de Braak e Braak, do CERAD (*Consortium to Establish a Registry for Alzheimer's Disease*) e do consórcio NIA-Reagan (National Institute of Aging-Reagan Institute). Casos com diagnósticos neuropatológicos diferentes de DA foram excluídos (n=27). **Resultados:** Os 62 casos foram classificados em: CDR0=39, CDR0,5=9, CDR≥1=14. Não havia diferenças quanto a idade, gênero e escolaridade entre os grupos. Os escores no CERAD correlacionaram-se melhor com os do CDR ($r=0,5303$; $p<0,001$). Os escores nos estágios de Braak e Braak foram significativamente mais elevados nos casos com CDR mais altos. A correlação do CDR com os escores dos critérios NIA-Reagan foi parcialmente rompida porque grande proporção de casos não se enquadrava em nenhuma das categorias diagnósticas destes critérios. **Conclusões:** Nesta casuística, os critérios do CERAD correlacionam-se melhor com os do CDR. Como observado por outros estudos, alguns casos de indivíduos cognitivamente normais, preencheram critérios neuropatológicos para o diagnóstico de DA.

Palavras-chave: doença de Alzheimer, demência, critérios diagnósticos, critérios neuropatológicos, banco de encéfalos, banco de cérebros.

¹Department of Pathology, University of São Paulo Medical School. ²Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo. ³Division of Geriatrics, University of São Paulo Medical School. ⁴Department of Preventive Medicine, University of São Paulo Medical School. ⁵Behavioral and Cognitive Neurology Unit, Department of Neurology, and Cognitive Disorders Reference Center (CEREDIC), Hospital das Clínicas of the University of São Paulo Medical School.

Lea Tenenholz Grinberg – Avenida Dr. Arnaldo, 455 / 1st floor / room 1351 - 01246-903 São Paulo SP - Brazil. E-mail: leagrinberg@usp.br

Received 10/11/2007. Received in final form 10/28/2007. Accepted 11/27/2007.

Dementia prevalence in Brazil is expected to increase by around 390% between 2001 and 2040.¹ A definitive diagnosis of Alzheimer's disease (AD) requires both a clinical history of dementia and neuropathologic confirmation at autopsy. Given that age-related changes overlap with early changes in AD, it is important to adopt neuropathologic criteria able to reliably distinguish between these two conditions. The currently used neuropathologic staging models of AD have been developed in the last 20 years. While the relationship of the maximum frequency of neuritic plaques (NP) with the age of the subject associated to the history of dementia are the pivotal constituents of the Consortium to Establish a Registry for Alzheimer's Disease criteria (CERAD),² the distribution and burden of neurofibrillary tangles (NFT) determine each of the seven Braak and Braak stages.³ Finally, the National Institute on Aging and the Ronald and Nancy Reagan Research Institute of the Alzheimer's Association⁴ proposed criteria for AD based on both NFT and NP (hereafter called NIA-Reagan criteria). The NIA-Reagan criteria stratifies cases by the likelihood that clinical dementia has been caused by AD lesions in the brain. Table 1 gives a summary of these criteria.

Although more than 10 years have passed since the last criteria were published, which of them best correlates with clinical symptoms remains a matter of debate. In addition, these criteria were largely tested in Caucasians of Northern European ancestry or in Asians⁵⁻⁷ and there may be biological differences in burden and distribution of AD changes among different ethnic groups.⁸ The Brazilian population is composed mainly of a mixture of Caucasians of Southern European ancestry, Africans and Indians. The purpose of this study was to examine which of the accepted neuropathologic criteria best discriminate AD from clinical

normal aging in a clinicopathological series of 89 subjects belonging to the Brazilian Brain Bank of the Aging Brain Study Group (BBBABSG).

Methods

A random sample of 89 retrospective cases belonging to the BBBABSG⁹ was studied. Brains were obtained from subjects aged 50 years or older sourced from the Sao Paulo Autopsy Service. Protocols were approved by the local ethics committee and written informed consent forms obtained.

The subjects' clinical and functional statuses were assessed through a reliable informant. The protocol included a series of semi-structured scales and questionnaires that covered major functional abilities and had been validated for assessment with an informant elsewhere.⁹ Clinical diagnosis of AD and vascular dementia were based on DSMIV-R and NINCDS-ADRDA,¹⁰ respectively as recommended by the Brazilian Academy of Neurology¹¹. The usual criteria were used for other dementias.^{12,13} Neuropathological examinations were carried out based on accepted criteria,⁹ using immunohistochemistry for β -amyloid (4G8), phospho-tau (PHF-1, gift from Peter Davies), α -synuclein (EQV-1, gift of Kenji Ueda) and where required, ubiquitin-1,

Out of the 89 cases, those having a neurodegenerative disease other than AD, or having dementia related to vascular changes were excluded.

The 62 remaining cases were divided into three groups according to the clinical dementia rating (CDR) score:¹⁴ CDR0=no cognitive decline; CDR0.5=questionable dementia and CDR \geq 1=dementia. The CDR groups were compared to the Braak and Braak stage, CERAD score and NIA-Reagan score.

Table 1. Summary of the neuropathologic criteria of Alzheimer's disease.

| Score name | Stage | Characteristics |
|----------------------------|-------------------------|--|
| Braak and Braak stage (BB) | 0 | Brain devoid of NFT† |
| | I-II | NFT† in transentorhinal and entorhinal regions |
| | III-IV | NFT† in the limbic allocortex and adjoining neocortex |
| | V-VI | NFT† in the neocortex, including the secondary and primary fields |
| CERAD* | Normal | No history of dementia and no NP‡ |
| | Possible | History of dementia and sparse number of NP‡ (age-related), or |
| | Probable | No history of dementia and moderate to severe number of NP (age-related) |
| | Definitive | History of dementia and sparse to moderate number of NP‡ (age-related) History of dementia and sparse to severe number of NP‡ (age-related) |
| NIA-Reagan | Normal | BB=0 and CERAD= normal |
| | Low likelihood | BB=I/II and CERAD= possible |
| | Intermediate likelihood | BB=III/IV and CERAD= probable |
| | High likelihood | BB=V/VI and CERAD= definitive |

*CERAD: the consortium to establish a registry for Alzheimer's disease; †NFT: neurofibrillary tangles; ‡NP: neuritic plaques.

Correlations were analyzed using the Spearman's rank correlation coefficient. The closer r is to one, the stronger the correlation. The r value was considered statistically significant when $p < 0.05$. Statistical analysis was performed using the software SPSS v. 13 (SPSS, Chicago, Illinois, USA).

Results

The CDR distribution and demographic data of the 62 selected subjects are described in Table 2. There were no differences regarding age, gender and education among those groups.

Table 3 depicts the distribution of the cases under each CDR group by the CERAD score, Braak and Braak stage and NIA-Reagan score. In 9 subjects, classification according to NIA-Reagan score was not possible due to discrepancies between CERAD score and Braak and Braak stage.

Table 4 shows the correlation among CDR score and neuropathologic criteria. CERAD score correlated best to the CDR scale (Table 4).

Table 2. Demographic data of the 62 subjects included in this study.

| Cognitive status | Number of subjects | Mean age (in years) | Male:female (%) |
|------------------|--------------------|---------------------|-----------------|
| CDR 0 | 39 | 69.7±12.1 | 61.5:38.5 |
| CDR 0.5 | 9 | 71.6±12.3 | 66.7:33.3 |
| CDR ≥1 | 14 | 82.9±4.9 | 50:50 |
| Total | 62 | 72.9±12.1 | 59.7:40.3 |

Discussion

In this series, the CERAD criteria correlated to the CDR score better than Braak and Braak score and NIA-Reagan criteria, although this moderate correlation was only slightly better than for the Braak and Braak score. Results diverge in the literature, with McKeel et al. in 2004¹⁵ finding NPs to be the best marker to differentiate normal controls from questionable dementia subjects, corroborating previous results,^{6,16} whereas some studies favor the Braak stage for best correlation to dementia severity.¹⁷

Table 3. Distribution of the cases in each CDR group by the CERAD score, Braak and Braak stage and NIA-Reagan score.

| | | CDR 0 | CDR 0.5 | CDR ≥1 | TOTAL |
|-----------------------|-------------------------|-------|---------|--------|-------|
| CERAD score | Normal | 29 | 7 | 6 | 42 |
| | Possible | 5 | 0 | 2 | 7 |
| | Probable | 2 | 1 | 2 | 5 |
| | Definitive | 3 | 1 | 4 | 8 |
| Braak and Braak stage | 0 | 18 | 2 | 1 | 21 |
| | I/II | 15 | 4 | 7 | 26 |
| | III/IV | 5 | 3 | 2 | 10 |
| | V/VI | 1 | 0 | 4 | 5 |
| NIA-Reagan score | Normal | 29 | 6 | 6 | 41 |
| | Low likelihood | 0 | 1 | 1 | 2 |
| | Intermediate likelihood | 4 | 0 | 2 | 6 |
| | High likelihood | 1 | 0 | 3 | 4 |
| | Criteria not met | 5 | 2 | 2 | 9 |

*CDR: clinical dementia rating.

Table 4. Clinicopathological correlation by score. The r and p values are depicted on first and second lines, respectively.

| Score name | CDR* | CERAD† | Braak and Braak | NIA-Reagan |
|-----------------|------------------|------------------|------------------|------------|
| CDR | 1.0000 | | | |
| CERAD | 0.5303 0.0000 | 1.0000 | | |
| Braak and Braak | 0.5294 0.0000 | 0.7563 0.0000 | 1.0000 | |
| NIA-Reagan | 0.5076 0.0002 | 0.9189 0.0000 | 0.9102 0.0000 | 1.0000 |

*CDR: clinical dementia rating; †CERAD: the consortium to establish a registry for Alzheimer's disease.

Despite the criteria, majority of studies comparing AD neuropathologic criteria have considered neurofibrillary tangle density and distribution to be directly proportional to severity of AD.¹⁸⁻²⁰ The present study corroborates these findings. In our series, 7.7% of the CDR0 subjects met Braak stages \geq IV, while 43% of the CDR \geq 1 subjects met the same stages.

The casuistic used to correlate NIA-Reagan criteria and CDR was reduced because nine subjects did not meet the criteria in order to be scored. NIA-Reagan criteria demand a perfect match between CERAD score and Braak stage. We are not the first to report problems in using the NIA-Reagan criteria. In 1997, Geddes et al. were only able to classify 22 out of their 47 cases using the NIA-Reagan criteria.²¹ They suggested accommodating discrepant cases having either a probable CERAD score or a limbic Braak and Braak stage, into the intermediate likelihood group of NIA-Reagan criteria. Also, Braak et al. in 1989 published results showing a mismatch between plaques and tangles in staging Alzheimer's pathology.²² Indeed, the *r* value of CERAD score and Braak and Braak stage correlation was 0.75. Therefore, the highly specific but low sensitivity NIA-Reagan criteria are most used for selecting well defined groups of cases for further analyses. If the prevalence of dementia of the casuistic is low or if the study focuses mainly on control subjects, specificity is usually the most important point and NIA-Reagan criteria are suggested for subject selection.

Perhaps, the current clinical criteria for AD might not be able to detect early changes. Corroborating this hypothesis, neuropathological diagnosis of AD was assigned to control clinical cases in several studies including the present.^{23,24} On the other hand, NP and NFT may be merely markers of AD. Giannakopoulos et al. demonstrated, in a large series of pure AD cases, that more than 50% of CDR scale variability was not explained by NFT or by amyloid deposits.⁷

The present study also has limitations. Informant-based clinicofunctional data might not be reliable enough for detecting early clinical changes. In order to enhance the sensitivity of our interview to early clinical changes, the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)²⁵ scale is used together with the CDR score. A study performed in Sao Paulo City verified the IQCODE's high sensitivity and specificity for the local population.²⁶ Furthermore, evidence has shown these scales to be reliable even for subjects having mild cognitive impairment.²⁷

In sum, this series involving Brazilian samples derived from a general autopsy service corroborates the results found in other clinicopathological series. These preliminary results show that our functional assessment has a good correlation with the neuropathological findings com-

pared to other series. Nevertheless, the clinicopathological correlation is not yet ideal and further studies may reveal better markers and criteria.

Grant support – FAPESP, Albert Einstein Research and Education Institute – Sao Paulo, CNPq, CAPES, LIM05-FMUSP, LIM01-FMUSP

References

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. *Lancet* 2005;366:2112-2117.
2. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;41:479-486.
3. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 1991;82:239-259.
4. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. *Neurobiol Aging* 1997;18:S1-S2.
5. Baner C, Jellinger K, Lassmann H, Fischer P, Leblhuber F. Correlations between mental state and quantitative neuropathology in the Vienna longitudinal study on dementia. *Eur Arch Psychiat Clin Neurosci* 1996;246:137-146.
6. Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. *Arch Neurol* 1998;55:326-335.
7. Giannakopoulos P, Gold G, Kovari E, et al. Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. *Acta Neuropathol* 2007;113:1-12.
8. Froehlich TE, Bogardus ST, Jr., Inouye SK. Dementia and race: are there differences between African Americans and Caucasians? *J Am Geriatr Soc* 2001;49:477-484.
9. Grinberg LT, Ferretti RE, Farfel JM, et al. Brain bank of the Brazilian aging brain study group - a milestone reached and more than 1,600 collected brains. *Cell Tissue Bank* 2007;8:151-162.
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34:939-944.
11. Nitrini R, Caramelli P, Bottino CM, Damasceno BP, Brucki SM, Anghinah R. Diagnosis of Alzheimer's disease in Brazil: diagnostic criteria and auxiliary tests. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. *Arq Neuropsiquiatr* 2005;63:713-719.

12. Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology*. 1998;51:1546-1554.
13. McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium. *Neurology*. 2005;65:1863-1872.
14. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. *Neurology*. 1993;43:2412-2414.
15. McKeel DW, Price JL, Miller JP, et al. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. *J Neuropathol Exp Neurol* 2004;63:1028-1037.
16. McKeel DW, Ball MJ, Price JL, et al. Interlaboratory histopathologic assessment of Alzheimer neuropathology: different methodologies yield comparable diagnostic results. *Alz Dis Assoc Disorder* 1993;7:136-151.
17. Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. *Neurobiol Aging* 1999;20:573-579.
18. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* 1992;42:631-639.
19. Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. *Arch Neurol* 1995;52:81-88.
20. Nagy Z, Esiri MM, Jobst KA et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. *Dementia* 1995;6:21-31.
21. Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery WR. Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. *Neurobiol Aging* 1997;18:S99-S105.
22. Braak H, Braak E, Ohm T, Bohl J. Alzheimer's disease: mismatch between amyloid plaques and neuritic plaques. *Neurosci Lett* 1989;103:24-28.
23. Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. *Neurology* 1996;46:707-719.
24. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia nondemented subjects with pathologically confirmed Alzheimer's disease. *Neurology* 1988;38:1682-1687.
25. Jorm AF, Jacomb PA. The informant questionnaire on cognitive decline in the elderly (IQCODE): Socio-demographic correlates, reliability, validity and some norms. *Psychol Med* 1989;19:1015-1022.
26. Bustamante SE, Bottino CM, Lopes MA, et al. Combined instruments on the evaluation of dementia in the elderly: preliminary results. *Arq Neuropsiquiatr* 2003;61:601-606.
27. Isella V, Villa L, Russo A, et al. Discriminative and predictive power of an informant report in mild cognitive impairment. *J Neurol Neurosurg Psychiatry* 2006;77:166-171.